Flosequinan: a new vasodilator for the treatment of heart failure.
The incidence and prevalence of congestive heart failure is increasing despite improvements in the management of myocardial infarction and hypertension. This trend is likely to continue as the proportion of elderly in the community increases. A new vasodilator, flosequinan, is currently under investigation and may improve prognosis.
Department of Medicine (Clinical Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London.
D P
DP
Dutka
J G
JG
Cleland
D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan